title: Tolerability of fosamprenavir/ritonavir associated with zidovudine-lamivudine used as postexposure prophylaxis for HIV infection.
authors.forename: Christine
authors.initials: C
authors.lastname: Burty
authors.forename: Simona
authors.initials: S
authors.lastname: Pavel
authors.forename: Kamel
authors.initials: K
authors.lastname: Ghomari
authors.forename: Annie
authors.initials: A
authors.lastname: Vermersch
authors.forename: Bernard
authors.initials: B
authors.lastname: Christian
authors.forename: Jean
authors.initials: J
authors.lastname: Pouaha
authors.forename: Yazdan
authors.initials: Y
authors.lastname: Yazdanpanah
authors.forename: Thierry
authors.initials: T
authors.lastname: May
authors.forename: Christian
authors.initials: C
authors.lastname: Rabaud
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D002219:Carbamates / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D005663:Furans; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D010755:Organophosphates / Q000008:administration & dosage / Q000009:adverse effects*; D011446:Prospective Studies; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*; D015215:Zidovudine / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D010755:Organophosphates; D013449:Sulfonamides; D019259:Lamivudine; D015215:Zidovudine; D019438:Ritonavir; C426859:fosamprenavir